Skip to content

OÜ PharmaTwo

Registry code (registrikood) 14436333Private limited company (Osaühing)VAT EE102063149Activity (EMTAK 47731): Ravimite jaemüükActive

Tallinn, Harju County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€2.8M
▼ 13.9% vs 2024
Profit before tax (2025)
-€35k
Employees, FTE (2025)
5
State taxes paid, last 4 quarters
€38k

Revenue, profit and employees, 2019–2025

€1.8M2019€2.3M2020€2.7M2021€3.1M2022€3.7M2023€3.2M2024€2.8M2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2019€1,827,639-€269,030-€300,598-€456,99013
2020€2,289,832-€190,344-€226,697-€653,63512
2021€2,664,553€122,551€86,296-€567,3401
2022€3,095,514€39,086€900-€566,4393
2023€3,696,086€80,693€20,535-€545,9044
2024€3,215,304-€1,922-€31,534-€577,4384
2025€2,767,414-€9,814-€35,011-€612,4495

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2019€30,440€847,743€1,304,733—-€456,990
2020€38,789€878,545€1,532,180—-€653,635
2021€44,012€862,515€1,429,855—-€567,340
2022€175,564€971,591€1,538,030—-€566,439
2023€54,357€584,106€1,130,010—-€545,904
2024€42,164€511,340€1,088,778—-€577,438
2025€70,709€396,227€1,008,676—-€612,449

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€0€4,727€753,3165
2022 Q2€0€6,356€724,7106
2022 Q3€11,267€10,794€687,0307
2022 Q4€4,394€10,919€847,4447
2023 Q1€6,302€10,451€864,0528
2023 Q2€2,699€11,470€787,0649
2023 Q3€69,502€12,539€1,088,47110
2023 Q4€3,313€11,758€966,83912
2024 Q1€8,437€13,118€822,60311
2024 Q2€7,550€14,811€780,96611
2024 Q3€9,932€16,985€786,23011
2024 Q4€13,061€17,004€863,14213
2025 Q1€9,301€18,267€790,92112
2025 Q2€13,137€22,416€768,75113
2025 Q3€36,420€28,758€720,7003
2025 Q4€15,574€13,692€568,4873
2026 Q1€11,013€13,494€597,5195
2026 Q2€10,391€13,251€558,8255
2026 Q3€1,339€14,697€612,90611

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), OÜ PharmaTwo reported revenue of €2,767,414.

The company recorded a net loss of €35,011 in the 2025 financial year.

Revenue decreased by 13.9% from €3,215,304 in 2024 to €2,767,414 in 2025.

Revenue grew at a compound annual rate of 7.2% between 2019 and 2025.

Equity accounted for -154.6% of total assets of €396,227 at the end of the 2025 reporting period.

With 5 full-time-equivalent employees in 2025, revenue per employee was €553,483.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, OÜ PharmaTwo reported €2,337,737 in turnover.

EMTA recorded 11 employees for the quarter ending Q3 2026, compared with 5 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.